ImVisioN GmbH - BioVisioN spins off new enterprise with peptide vaccine portfolio
13-Dec-2004 -
BioVisioN announces the spin-off of a drug portfolio for causative
treatment of allergic diseases - This drug portfolio may lead the way to a
new concept for vaccination applicable also to other indications.
Today the CEO of the Hannover, Germany based company BioVisioN AG, Dr.
Sven Rohmann, ...
allergic diseases
allergic rhinitis
allergies
+7